Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition.
Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition.
复制标题
DOI：
10.1182/blood.v63.1.128.128
复制
发表时间：
1984
期刊：
影响因子：
20.3
通讯作者：
Andrei Z. Budzynski;Bharat V. Pandya;Ronald N. Rubin;B. S. Brizuela;Robert L. Jones;Lois Jovanovic;Steven Forman;Cheryl F. Scott;Dipali Sinha;F. Seaman;Peter N. Walsh;Betty P. Barton;Hernan E. Grenett;Robert A. Bergamini;Peter J. Quesenberry;Michael A. Coppola;Richard J. Gualtieri;Philip M. Wade;Zengxuan Song;Michael A. Doukas;C. E. Shideler;Donald G. Baker;J. J. Sixma-J.;K. Sakariassen;N. Beeser-Visser;Mieke Otienhof-Rovers;P. Bolhuis
中科院分区：
文献类型：
--
作者：
Andrei Z. Budzynski;Bharat V. Pandya;Ronald N. Rubin;B. S. Brizuela;Robert L. Jones;Lois Jovanovic;Steven Forman;Cheryl F. Scott;Dipali Sinha;F. Seaman;Peter N. Walsh;Betty P. Barton;Hernan E. Grenett;Robert A. Bergamini;Peter J. Quesenberry;Michael A. Coppola;Richard J. Gualtieri;Philip M. Wade;Zengxuan Song;Michael A. Doukas;C. E. Shideler;Donald G. Baker;J. J. Sixma-J.;K. Sakariassen;N. Beeser-Visser;Mieke Otienhof-Rovers;P. Bolhuis
采用人肾动脉和脐动脉，在环形灌注室中研究了凝血因子VIII-血管性血友病因子（FVIII-vWF）的多聚体大小与血小板粘附于内皮下的支持之间的关系。含有低分子量多聚体的商业因子VIII浓缩物在输注到患有血管性血友病的患者中时显示不校正出血时间，其不支持灌注室中的血小板粘附。冷沉淀物和两种实验性FVIII-vWF浓缩物含有高分子量多聚体，支持血小板粘附。将从冷沉淀物中纯化的因子VIII-vWF细分为三个不同分子量的级分（6.0-14.0、4.0-9.0和3.0-7.5 × 10（6）道尔顿）。这些组分似乎同样良好地结合，并且在支持血小板粘附方面同样有效。通过部分还原制备具有低分子量（0.5-1.5 × 10（6）道尔顿）的多聚体的因子VIII-vWF。FVIII-vWF与内皮下的结合没有受损，血小板粘附的支持似乎比瑞斯托康辅助因子活性更能抵抗减少的影响。在高剪切速率（2，500 sec-1）下，观察到血小板粘附增加，FVIII-vWF部分降低。这些数据表明，FVIII-vWF制剂纠正出血时间的能力反映在灌注室中血小板与内皮下的粘附增强。这些数据还强调了多聚体大小不是决定FVIII-vWF是否支持血小板粘附的唯一因素。
The relationship between the multimeric size of factor VIII-von Willebrand factor (FVIII-vWF) and the support of platelet adhesion to subendothelium was studied in an annular perfusion chamber, employing human renal and umbilical arteries. Commercial factor VIII concentrates containing multimers of low molecular weight that had been shown not to correct the bleeding time upon infusion into patients with von Willebrand's disease did not support platelet adhesion in the perfusion chamber. Cryoprecipitate and two experimental FVIII-vWF concentrates containing multimers of high molecular weight supported platelet adhesion. Factor VIII-vWF purified from cryoprecipitate was subdivided into three fractions of different molecular weights (6.0-14.0, 4.0-9.0, and 3.0-7.5 X 10(6) dalton). These fractions appeared to bind equally well and to be equally effective in supporting platelet adhesion. Factor VIII-vWF with multimers of low molecular weight (0.5-1.5 X 10(6) dalton) were prepared by partial reduction. Binding of FVIII-vWF to subendothelium was not impaired, and the support of platelet adhesion appeared to be more resistant to the effect of reduction than the ristocetin cofactor activity. At high shear rate (2,500 sec-1), increased platelet adhesion was observed with partially reduced FVIII-vWF. These data indicate that the ability of FVIII-vWF preparations to correct the bleeding time is reflected in enhanced platelet adhesion to subendothelium in a perfusion chamber. These data also emphasize that multimeric size is not the only factor determining whether FVIII-vWF will support platelet adhesion.